Hendrik Neubert

About

Hendrik Neubert is a leading figure in bioanalytical chemistry, specializing in the development of ultrasensitive mass spectrometry-based assays for protein biomarkers and biotherapeutics. His core research focuses on hybrid immunoaffinity capture and LC-MS/MS methodologies, enabling precise quantification of low-abundance proteins in complex biological matrices. A hallmark contribution is his pioneering work on sequential protein and peptide immunoaffinity capture, demonstrated in his highly cited 2012 study on total human β-nerve growth factor (NGF). This assay, which achieved 127 citations, was critical for supporting clinical trials of tanezumab, a monoclonal antibody for chronic pain, by accurately measuring NGF levels. Neubert further advanced the field with his 2010 assay for matrix metalloproteinase 9 in mouse serum (69 citations), showcasing his ability to translate complex proteomic challenges into robust, reproducible workflows. His work has profoundly impacted pharmaceutical development, providing the analytical rigor needed to validate target engagement and pharmacokinetics. Through these innovations, Neubert has established himself as a key architect of modern quantitative proteomics, bridging the gap between discovery research and clinical application.

Research Focus

Key Achievements

Top Papers

1. 1
   Sequential Protein and Peptide Immunoaffinity Capture for Mass Spectrometry-Based Quantification of Total Human β-Nerve Growth Factor

   127 citations · 2012
2. 2
   An immunoaffinity liquid chromatography–tandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum

   69 citations · 2010

Key Collaborators

Contact & Links